Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay
Journal of the European Academy of Dermatology and Venereology · 2026-08 · 40 (8) · 1359-1371
DOI: 10.1111/jdv.70442 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 13.04.2026. Verfasst von Lian F van der Gang und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Centre Utrecht, Utrecht, The Netherlan…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LEO Pharma.
Abstract (Originalsprache)
Background
Dupilumab and tralokinumab for atopic dermatitis (AD) target the type 2 axis through different mechanisms of action, which may lead to variation in effectiveness and safety. Head‐to‐head trials, however, are lacking.
Objectives
To compare the real‐world effectiveness and safety of dupilumab and tralokinumab in AD.
Methods
This prospective cohort study enrolled biologic−/Janus kinase inhibitor‐naïve AD patients (≥12 years) from the BioDay registry who initiated dupilumab or tralokinumab between November 2021 and September 2024. Visits were scheduled at baseline, 4 weeks and every 3 months up to 52 weeks. Effectiveness outcomes included Eczema Area and Severity Index (EASI), weekly mean pruritus Numeric Rating Scale (NRS), treat‐to‐target thresholds (EASI ≤ 7; NRS‐pruritus ≤ 4, with patients discontinuing treatment considered non‐responders) and drug survival. Adverse events (AEs) were assessed at each visit. Inverse probability of treatment weighting (IPTW) was used to balance treatment groups.
Results
In total, 750 patients were included (643 dupilumab; 107 tralokinumab). After IPTW, baseline characteristics were well balanced. During follow‐up, dupilumab patients had lower EASI scores than tralokinumab patients, although differences were not consistently statistically significant ( p = 0.10). NRS‐pruritus scores were significantly lower with dupilumab at all visits ( p < 0.0001), mean differences did not exceed the 2‐point clinical relevance threshold. The probability of achieving EASI ≤ 7 and NRS‐pruritus ≤ 4 was higher with dupilumab (both p < 0.0001), with risk differences of 34.7% and 40.2% at 52 weeks, respectively. After 52 weeks, dupilumab drug survival was 92.6% vs. 70.6% for tralokinumab. Ocular surface disease incidence was similar (HR 1.0, 95% CI 0.6–1.6, p = 0.94) between treatments, leading to discontinuation of dupilumab in n = 23 (3.4/100 PY) and tralokinumab in n = 5 (5.4/100 PY).
Conclusions
In this real‐world comparison, dupilumab provided superior effectiveness compared with tralokinumab. In responders continuing treatment, EASI and NRS‐pruritus differences were small. More substantial differences were observed when treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4, and discontinuation rates were taken into account.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
- Department of Dermatology, Reinier de Graaf Hospital, Delft, The Netherlands.
- Department of Dermatology, Frisius Medical Centre, Leeuwarden, The Netherlands.
- Department of Dermatology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
ORCID-Profile: Lian F van der Gang, Antoni Gostynski
Förderung
- LEO Pharma
Zitieren
APA
van der Gang, L. F., Zuithoff, N. P. A., Haeck, I. M., Harbers, V. E. M., Stadhouders-Keet, S., Politiek, K., Oosting, A. J., van Lynden-van Nes, A. M. T., Lam, H. Y., van Tuyll van Serooskerken, A. M., Stewart, S. M., Gostynski, A., Flinterman, A., Velstra, B., Touwslager, W. R. H., van Erp, F. C., Schuttelaar, M. L. A., de Bruin-Weller, M. S., & de Graaf, M. (2026). Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay. Journal of the European Academy of Dermatology and Venereology, 40(8), 1359-1371. https://doi.org/10.1111/jdv.70442
Vancouver
van der Gang LF, Zuithoff NPA, Haeck IM, Harbers VEM, Stadhouders-Keet S, Politiek K, et al. Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay. Journal of the European Academy of Dermatology and Venereology. 2026;40(8):1359-1371. doi:10.1111/jdv.70442
BibTeX
@article{vanderGang2026,
author = {van der Gang, Lian F and Zuithoff, Nicolaas P A and Haeck, Inge M and Harbers, Veroniek E M and Stadhouders-Keet, Simone and Politiek, Klaziena and Oosting, Albert J and van Lynden-van Nes, Anneke M T and Lam, Hoo-Yin and van Tuyll van Serooskerken, Anne-Moon and Stewart, Shiarra M and Gostynski, Antoni and Flinterman, Annebeth and Velstra, Berit and Touwslager, Wouter R H and van Erp, Francine C and Schuttelaar, Marie L A and de Bruin-Weller, Marjolein S and de Graaf, Marlies},
title = {Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {8},
pages = {1359--1371},
doi = {10.1111/jdv.70442}
}
EUVIMED